

# Ralph P Maguire

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9066254/publications.pdf>

Version: 2024-02-01

32  
papers

13,945  
citations

304743

22  
h-index

434195

31  
g-index

35  
all docs

35  
docs citations

35  
times ranked

20135  
citing authors

#	ARTICLE	IF	CITATIONS
1	An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. <i>NeuroImage</i> , 2006, 31, 968-980.	4.2	10,125
2	Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2007, 27, 1533-1539.	4.3	1,840
3	Safety, tolerability, and antibody response of active A $\beta$ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. <i>Lancet Neurology</i> , The, 2012, 11, 597-604.	10.2	261
4	Activation of the human brain by monetary reward. <i>NeuroReport</i> , 1997, 8, 1225-1228.	1.2	246
5	Changes in cortical grey matter density associated with long-standing retinal visual field defects. <i>Brain</i> , 2009, 132, 1898-1906.	7.6	173
6	Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study. <i>Journal of Neurology</i> , 2016, 263, 1287-1295.	3.6	158
7	Effects of intravenous glucose on dopaminergic function in the human brain in vivo. <i>Synapse</i> , 2007, 61, 748-756.	1.2	122
8	Striatal dopa and glucose metabolism in PD patients with freezing of gait. <i>Movement Disorders</i> , 2006, 21, 1326-1332.	3.9	107
9	Active A $\beta$ immunotherapy CAD106 in Alzheimer's disease: A phase 2b study. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 10-22.	3.7	102
10	Kinetic Modeling of the Serotonin 5-HT <sub>1B</sub> Receptor Radioligand [ <sup>11</sup> C]P943 in Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 196-210.	4.3	83
11	Cerebral glucose metabolism in patients with spasmodic torticollis. <i>Movement Disorders</i> , 1997, 12, 704-708.	3.9	78
12	Assessment of a white matter reference region for <sup>11</sup> C-UCB-J PET quantification. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2020, 40, 1890-1901.	4.3	77
13	Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). <i>Psychiatry Research - Neuroimaging</i> , 1998, 83, 149-162.	1.8	68
14	Dissociable effects of methylphenidate, atomoxetine and placebo on regional cerebral blood flow in healthy volunteers at rest: A multi-class pattern recognition approach. <i>NeuroImage</i> , 2012, 60, 1015-1024.	4.2	67
15	Arterial transit time effects in pulsed arterial spin labeling CBF mapping: Insight from a PET and MR study in normal human subjects. <i>Magnetic Resonance in Medicine</i> , 2010, 63, 374-384.	3.0	58
16	Evaluation of [ <sup>11</sup> C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates. <i>NeuroImage</i> , 2011, 56, 268-279.	4.2	50
17	A single-center, open-label positron emission tomography study to evaluate brivaracetam and levetiracetam synaptic vesicle glycoprotein 2A binding in healthy volunteers. <i>Epilepsia</i> , 2019, 60, 958-967.	5.1	45
18	Effect of fenfluramine-induced increases in serotonin release on [ <sup>18</sup> F]MPPF binding: A continuous infusion PET study in conscious monkeys. <i>Synapse</i> , 2006, 59, 18-26.	1.2	40

#	ARTICLE	IF	CITATIONS
19	TCH346 prevents motor symptoms and loss of striatal FDOPA uptake in bilaterally MPTP-treated primates. <i>Neurobiology of Disease</i> , 2003, 14, 205-217.	4.4	35
20	Methylphenidate-induced activation of the anterior cingulate but not the striatum: A [15O]H2O PET study in healthy volunteers. <i>Human Brain Mapping</i> , 2007, 28, 625-635.	3.6	34
21	Validation of Parametric Methods for [11C]UCB-J PET Imaging Using Subcortical White Matter as Reference Tissue. <i>Molecular Imaging and Biology</i> , 2020, 22, 444-452.	2.6	28
22	Striatal FDOPA uptake and cognition in advanced non-demented Parkinson's disease: A clinical and FDOPA-PET study. <i>Parkinsonism and Related Disorders</i> , 2008, 14, 224-228.	2.2	25
23	Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[18F]FMeNER-D2. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1308-1314.	6.4	23
24	Functional magnetic resonance imaging of brightness induction in the human visual cortex. <i>NeuroReport</i> , 2005, 16, 1335-1338.	1.2	19
25	Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptorsâ€”The cases of ketamine and haloperidol. <i>Neurochemistry International</i> , 2008, 53, 45-50.	3.8	18
26	An Investigation of Multiple Time/Graphical Analysis Applied to Projection Data: Theory and Validation. <i>Journal of Computer Assisted Tomography</i> , 1997, 21, 327-331.	0.9	15
27	Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntingtonâ€™s disease: a preliminary investigation in the postmortem human brain. <i>Brain Structure and Function</i> , 2015, 220, 3043-3051.	2.3	14
28	Cerebral Metabolic Effects of Intravenous Glycine in Healthy Human Subjects. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 595-599.	1.4	12
29	Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 71, 66-75.	4.8	8
30	A Comparative Study of inâ€¦..vitro Assays for Predicting the Nonspecific Binding of PET Imaging Agents inâ€¦..vivo. <i>ChemMedChem</i> , 2020, 15, 585-592.	3.2	8
31	Regional brain mGlu5 receptor occupancy following single oral doses of mavoglurant as measured by [11C]-ABP688 PET imaging in healthy volunteers. <i>NeuroImage</i> , 2021, 230, 117785.	4.2	6
32	Molecular Imaging Biomarkers as a Tool in Development of Novel Medicines. , 2012, , 33-48.		0